Search hospitals > Ohio > Columbus
The Mark H Zangmeister Center
Claim this profileColumbus, Ohio 43219
Global Leader in Cancer
Global Leader in Lung Cancer
Conducts research for Breast Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Adenocarcinoma
275 reported clinical trials
7 medical researchers
Summary
The Mark H Zangmeister Center is a medical facility located in Columbus, Ohio. This center is recognized for care of Cancer, Lung Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Adenocarcinoma and other specialties. The Mark H Zangmeister Center is involved with conducting 275 clinical trials across 408 conditions. There are 7 research doctors associated with this hospital, such as Timothy D. Moore, Jeanna L Knoble, Sameh Mikhail, MD, and Emily Whitman.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Lung Cancer
Global LeaderStage IV
Stage III
Stage II
Top PIs
Timothy D. MooreThe Mark H Zangmeister Center4 years of reported clinical research
Expert in Cancer
Expert in Lung Cancer
126 reported clinical trials
208 drugs studied
Jeanna L KnobleZangmeister Cancer Center2 years of reported clinical research
Studies Breast Cancer
Studies Cancer
3 reported clinical trials
11 drugs studied
Sameh Mikhail, MDZangmeister Cancer Center3 years of reported clinical research
Studies Colorectal Cancer
Studies Ovarian Cancer
2 reported clinical trials
3 drugs studied
Emily WhitmanZangmeister Cancer Center4 years of reported clinical research
Studies Ovarian Cancer
Studies Ovarian Tumors
2 reported clinical trials
4 drugs studied
Clinical Trials running at The Mark H Zangmeister Center
Breast Cancer
Lung Cancer
Non-Small Cell Lung Cancer
Cancer
Bladder Carcinoma
Melanoma
Ovarian Cancer
Cutaneous Melanoma
Bladder Cancer
Pancreatic Cancer
Sacituzumab Govitecan
for Triple-Negative Breast Cancer
The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) versus treatment of physician's choice (TPC) in participants with previously untreated, locally advanced, inoperable or metastatic triple-negative breast cancer whose tumors do not express programmed cell death ligand 1 (PD-L1) or in participants previously treated with anti-programmed cell death (ligand or protein) 1 (Anti-PD-(L)1) Agents in the early setting whose tumors do express PD-L1.
Recruiting4 awards Phase 3
Sacituzumab Govitecan + Pembrolizumab
for Triple-Negative Breast Cancer
The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) and pembrolizumab versus treatment of physician's choice (TPC) and pembrolizumab in participants with previously untreated, locally advanced inoperable or metastatic triple-negative breast cancer, whose tumors express programmed cell death ligand 1 (PD-L1).
Recruiting4 awards Phase 3
Support Program
for Breast Cancer
This study is evaluating whether a support program may help breast cancer patients take their medication correctly.
Recruiting2 awards Phase 34 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at The Mark H Zangmeister Center?
The Mark H Zangmeister Center is a medical facility located in Columbus, Ohio. This center is recognized for care of Cancer, Lung Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Adenocarcinoma and other specialties. The Mark H Zangmeister Center is involved with conducting 275 clinical trials across 408 conditions. There are 7 research doctors associated with this hospital, such as Timothy D. Moore, Jeanna L Knoble, Sameh Mikhail, MD, and Emily Whitman.